Noristerat provides dependable, short-term hormonal contraception. It is applied in the management of reproductive health specifically to mitigate the risk of unintended conception. The primary therapeutic benefit is establishing a state of sustained protection for an extended duration, which supports patients seeking to maintain control over family planning.

This medication is relevant for easing symptom clusters that may become intense or disruptive, relevant to adherence requirements. It is commonly used as a non-daily regimen, and its indications include providing early supportive protection in the postpartum phase, serving as a contraceptive bridge (e.g., until a partner’s vasectomy is effective), and use by women who are medically restricted from using estrogen-containing methods.

“This method assists with maintaining a sense of stability when symptoms are more noticeable, relevant to frequent dosing schedules.”

This convenience contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with the requirements of consistent birth control.

---

Quick Fact: Relief for Risk of Unintended Conception Noristerat is commonly used across conditions presenting with acute episodes, relevant when supportive symptom management is appropriate, and may assist with managing symptoms that interfere with daily functioning.

Noristerat (norethisterone enanthate) is intended only for women of reproductive age seeking short-term, reversible contraception. Official regulatory documents establish specific restrictions and contraindications that govern population eligibility.

Populations for Whom Use is Contraindicated

Use of Noristerat is strictly prohibited if a patient has any of the following conditions, as they constitute absolute contraindications:

• Known or suspected pregnancy.
• Active or history of severe hepatic disease or liver tumors (benign or malignant).
• Current venous or arterial thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism, stroke, or heart attack).
• Severe diabetes mellitus with vascular changes.
• Pathologically increased blood pressure.
• Known or suspected sex-steroid influenced malignancies (e.g., certain breast or genital cancers).
• Undiagnosed vaginal bleeding.

Age and Condition-Based Restrictions

Age-related eligibility is restricted to post-menarcheal women, and the medicine is not indicated after menopause for contraception. While use during lactation is generally possible, it is not recommended in women less than six weeks postpartum who are primarily breastfeeding. Furthermore, official labeling requires special consideration or caution for patients with conditions such as impaired renal function, severe depression, or diabetes mellitus without vascular changes.

Interactions with other medicines and products

This section describes interactions of Norethisterone enantate as documented in official government regulatory sources, classified by their official effects.

Category	Official Regulatory Statement or Entity
Medicinal Product Classes	Hepatic enzyme inducers (e.g., certain Anticonvulsants, Antimicrobials); CYP3A4 Inhibitors; Hepatitis C combination products; Oral Antidiabetics/Insulin.
Specific Interacting Medicines	Anticonvulsants (e.g., Phenytoin, Carbamazepine); Antimicrobials (e.g., Rifampicin, Griseofulvin); Azole Antifungals; Macrolides; St. John's Wort.
Mechanistic Basis	Hepatic microsomal enzyme induction (reduced efficacy); CYP3A4 inhibition (increased exposure); effect on glucose tolerance.
Timing-Based Rules	The oily solution for intramuscular injection must not be mixed with any other medicinal product.
Interaction Restrictions	Contraindicated co-administration with specific Hepatitis C drug combinations (ombitasvir, paritaprevir, or dasabuvir).

Official Interaction Statements

• Co-administration with medicinal products that induce hepatic microsomal enzymes may lead to a reduction in contraceptive effectiveness due to increased clearance of the progestin component.
• Strong and moderate CYP3A4 inhibitors are documented to potentially increase the plasma concentrations of the progestin.
• The herbal remedy St. John's Wort (Hypericum perforatum) may reduce contraceptive effectiveness due to enzyme induction.
• The medication may affect the metabolism of other drugs, potentially influencing the concentration of substances such as Ciclosporin or the effectiveness of oral antidiabetics.

The regulatory profile emphasizes pharmacokinetic interactions, noting that substances which accelerate metabolism (enzyme inducers) may compromise the efficacy of Noristerat, while inhibitors may increase its exposure. Furthermore, the official labeling mandates a procedural constraint that the sterile injection solution must not be mixed with other products, and formally contraindicates co-use with certain Hepatitis C antiviral regimens.

Noristerat contains norethisterone enanthate (NET-EN), an ester prodrug that, following deep intramuscular administration, undergoes hydrolysis to release the active compound, norethisterone (NET). NET functions as an agonist at intracellular progesterone receptors (PRs) located in target tissues such as the hypothalamus, pituitary gland, cervix, and endometrium.

.

The binding of NET to the PR initiates a conformational change, leading to receptor dimerization and binding to specific DNA response elements. This transcription factor activity modulates the expression of target genes. In the hypothalamus and pituitary gland, this molecular signaling exerts negative feedback, resulting in the suppression of Gonadotropin-Releasing Hormone (GnRH) secretion and a subsequent reduction in the pituitary release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

System-level physiological modulation primarily involves the inhibition of the LH surge, which prevents the final maturation and release of an oocyte from the ovary, a process termed anovulation. Concurrently, NET acts on the cervical glandular epithelium to increase the viscosity and decrease the volume of the cervical mucus, establishing a structural barrier to sperm passage. Finally, it induces decidualization and atrophy of the endometrium, rendering the uterine lining non-receptive to blastocyst nidation.

Noristerat (norethisterone enantate) is administered as a deep intramuscular injection into the gluteal (buttock) muscle or, alternatively, the upper arm deltoid muscle.

Dosing and Scheduling

Injection Schedule	Interval
First Injection	Within the first 5 days of the menstrual cycle (Day 1 is the start of bleeding).
Follow-up Injections 2, 3, and 4	Every 8 weeks
Subsequent Injections	Every 12 weeks (84 days)

• Dose: 200 mg Norethisterone Enantate (NETE) as a single injection provides contraception for the scheduled interval.
• Preparation: Due to the oily solution's viscosity, the ampoule is immersed in warm water before injection to facilitate administration. A needle of at least medium bore is used.
• Administration Procedure: The injection is administered extremely slowly. The procedure includes placing a plaster over the injection site afterward to prevent reflux of the solution.
• Missed Dose: If the subsequent injection is delayed beyond the 8- or 12-week interval, contraceptive protection is no longer assured from the 9th or 13th week, respectively, and additional barrier contraceptive methods are used.
• Switching Methods: When switching from a combined oral contraceptive (COC), the first Noristerat injection is typically given immediately after the last active COC tablet. If starting later, a barrier method is used for the first 7 days.

Noristerat: Recent Clinical Evidence

Evidence for Contraceptive Use

The core research for Noristerat, based on systematic reviews, large observational studies, and randomized controlled trials (RCTs), has studied its role in preventing pregnancy for women of reproductive age. These studies primarily examined the rate of pregnancy prevention and monitored measurements related to hormonal suppression. Studies reported patterns observed during clinical evaluation that were associated with the measured prevention of pregnancy. Trials also described the measurements related to the time taken for fertility to return following the cessation of the medicine.

Observational data and clinical studies reported patterns of discontinuation, often noting that changes in menstrual bleeding were the primary reason for stopping use. Comparative trials described differences between Noristerat and other progestogen injections regarding their effects on hormonal suppression and menstrual bleeding characteristics.

---

Follow-up, Specific Groups, and Limitations

Research has also been evaluated in specific clinical situations, such as women immediately following childbirth (postpartum) and those evaluated for use of a non-estrogen method. For postpartum use, studies explored whether the injection was associated with any outcomes related to changes in the mother’s milk supply or the infant's development. Systematic reviews described patterns observed, suggesting that the medicine may not negatively affect the duration of breastfeeding.

A frequently noted limitation in the research record is related to the long-term outcomes of the injection, as research primarily focused on short-term usage (e.g., 8-week cycles). Follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes that extend past the typical one-year mark. Furthermore, sample sizes were modest in some older trials, and evidence quality varies across studies based on the methodology used, meaning results apply only to the populations studied.

Common questions about Noristerat (FAQ)

Q: How quickly does Noristerat start to work?

A: Official product information describes the start of contraceptive protection based on when the first injection is received. If the injection is given within the first five days of the menstrual cycle, contraceptive protection is established immediately. If it is started at any other time, an additional barrier method is required for the first seven days, according to official administration guidelines.

Q: How long does Noristerat stay in my system?

A: Noristerat is formulated as a depot injection, meaning the active ingredient is released slowly from the muscle into the bloodstream. This design is what ensures a continuous level of medication for the entire scheduled interval of 8 to 12 weeks. The formulation is designed to provide continuous contraceptive coverage over this duration.

Q: What should I do if I forget to mention a specific medication I'm taking?

A: The official labeling highlights the importance of disclosing all medications, as some can reduce the effectiveness of Noristerat. If a medication omission is discovered, official regulatory guidance indicates that consultation with a healthcare provider is necessary for advice on whether additional contraceptive precautions, such as condoms, are required and for how long.

Q: Can the injection site feel sore or bruised after Noristerat is given?

A: While the Noristerat regulatory label may list general local reactions, reports from patients using depot injections include occurrences of temporary soreness, tenderness, or nodule formation at the injection site. This is a possibility often noted with this form of administration.

Q: Does Noristerat affect bone density?

A: Progestogen-only injectables, as a class, are sometimes associated with a temporary decrease in bone mineral density (BMD). Official regulatory documents state that for long-term use, the benefits and risks of continued use must be periodically reviewed by a healthcare professional.

Q: Why is Noristerat sometimes used for non-contraceptive reasons?

A: The sole therapeutic indication for Noristerat, according to official regulatory documents, is contraception. Use for any other reason is not addressed in the product labeling.

Q: What should I do if I experience an unfamiliar side effect?

A: The patient information leaflet states that consultation with a healthcare provider is necessary if you experience any severe or unfamiliar symptoms. This includes reporting any potential severe adverse reactions, such as severe abdominal pain, or concerning mood changes and depressive symptoms.

Q: Does Noristerat make you feel tired or fatigued?

A: The official side effect profile includes terms related to the central nervous system. Lethargy is a term used in clinical studies and related product reports, which may include the feelings of tiredness or fatigue.

Q: What type of medical professional typically administers Noristerat?

A: Noristerat is classified as a prescription-only medicine that requires deep intramuscular injection, which must be administered slowly. The technical nature and precise administration instructions for the depot injection mean it is necessary for a trained healthcare professional, such as a doctor or nurse, to administer the medicine.

Q: What are the signs of a potential allergic reaction to Noristerat?

A: Hypersensitivity (allergy) to the active substance or its components is listed as a contraindication. Official regulatory guidance notes that signs of an allergic reaction, such as swelling of the face or throat (angioedema), may occur and require immediate assessment by a healthcare professional.

Q: What information should I read before getting the Noristerat injection?

A: Regulatory labeling requires that a thorough medical examination and assessment of all contraindications and warnings take place before the injection is given. The official patient information leaflet must be read to understand the expected effects, potential risks, and necessary precautions described in the regulatory labeling.

Q: What does the term 'progestogen-only' mean for Noristerat?

A: Noristerat is officially classified as a progestogen-only contraceptive. This means that its formulation contains only one type of synthetic hormone, norethisterone enantate, and does not contain any estrogen component.

Q: Does Noristerat protect against sexually transmitted infections (STIs)?

A: Official warnings consistently state that hormonal contraceptives, including progestogen-only methods, do not protect against sexually transmitted infections (STIs), including HIV infection (AIDS). Protection against STIs is achieved through barrier methods, such as condoms.

Q: Does using Noristerat affect the results of blood tests?

A: Regulatory safety information indicates that the drug may influence certain metabolic factors. Specifically, Noristerat is documented to potentially affect glucose tolerance and lipid profiles. These changes may influence the results of corresponding blood tests.

Q: Does Noristerat interact with common over-the-counter pain relievers?

A: The official Noristerat information primarily details interactions with prescription drugs and herbal remedies that affect liver enzymes. Regulatory data on the active ingredient (norethindrone) does not suggest any known major interaction with widely used, over-the-counter pain relievers such as acetaminophen.

Q: Is Noristerat safe for people with a history of migraines?

A: Official warnings state that people who suffer from migraines or have a history of specific types of vascular diseases should use the medicine with special caution. Regulatory guidance requires that individual eligibility be determined by a healthcare provider, who will assess the specific health history against the official warnings.

Q: Is there any difference between Noristerat and Depo-Provera?

A: Both are classified as progestogen-only injectable contraceptives. However, official information shows they differ in their core composition: Noristerat contains Norethisterone Enanthate, while Depo-Provera contains Medroxyprogesterone Acetate. They also have different administration schedules (Noristerat is typically 8 or 12 weeks; Depo-Provera is typically 12 weeks).

Q: Can Noristerat cause mood changes or depression?

A: Official warnings note that some women using hormonal contraceptives have reported experiencing depressed mood or depression. Regulatory documentation states that consultation with a healthcare provider is necessary if concerning mood changes or depressive symptoms are experienced.

Q: How does Noristerat compare to oral contraceptives regarding efficacy?

A: Clinical trial evidence examined by public health regulatory bodies suggests that the efficacy of injectable regimens, including Noristerat, compares favorably with the effectiveness of oral contraceptives in preventing pregnancy when used as directed.

Q: What is the risk of having a serious interaction with Noristerat?

A: The official product labeling specifies that interactions with enzyme-inducing medicinal products can lead to a reduction in contraceptive effectiveness. Furthermore, co-administration with certain Hepatitis C combination treatments is formally contraindicated (prohibited).

Q: Can Noristerat be used during perimenopause?

A: The official product labeling states that Noristerat is not indicated for contraception after menopause. Eligibility for the transition period leading up to menopause (perimenopause) is not explicitly defined in the indication, and eligibility requires determination by a healthcare professional as part of the initial medical examination.

Official Storage and Disposal Requirements

The storage and disposal of Noristerat (norethisterone enantate injection) must adhere strictly to the conditions specified in the official regulatory labeling to ensure product stability and safety.

Requirement Type	Official Labeled Condition
Temperature	Store below 25 C
Protection	Must be protected from light
Shelf Life	5 years (when stored correctly)

The product must be kept out of the sight and reach of children as a mandatory safety measure. The disposal of any unused medication or waste materials, such as the empty ampoule, is required to be carried out in accordance with local regulations for pharmaceutical waste.